InvestorsHub Logo
Followers 163
Posts 12756
Boards Moderated 1
Alias Born 01/26/2016

Re: Poor Man - post# 684902

Friday, 04/12/2024 7:53:55 PM

Friday, April 12, 2024 7:53:55 PM

Post# of 688470
Poor Man -,

One obvious reason NWBO might have chosen to submit first with MHRA is that a cash strapped company needed to wait out guidance changes at FDA where big pharma has considerable influence. They might have also considered the promising innovative medicine (PIM) and National Priority designations as a sign that MHRA was ready to act favorably without the heavy influence of big pharma getting in the way. No designations like that in the states anywhere to be seen.
Linda understands leverage and big pharma has it with FDA, media and politicians. Consider that no politicians are openly talking about DCVax in the US and yet in the UK there are discussions about the need for brain tumor research, trials and other which leads to mentions of DCVax in those circles. The media has been almost dead silent about advances with DCVax development while Cambridge outlets and others have been talking about NWBO and Advent. MHRA is likely more influenced by high ranking clinicians like Dr Keyoumars Ashkan and advocacy groups than by big pharma. All in all there is a more favorable climate in the UK than in the USA. Linda will always start where she has a better chance to gain traction and a few years back she and others were able to be present with government officials at a health care meeting that I think Lykiri shared pictures of. I have never seen anything like that happen in the USA. Best wishes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News